Tramadol

證據等級: L5

預測適應症: 10 個

Tramadol: From Unspecified Indication to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Tramadol’s original approved indication is not recorded in this evidence pack, and no formal mechanism-of-action (MOA) entry is available. The TxGNN model’s top-ranked prediction — acromesomelic dysplasia, Hunter-Thompson type — has 0 clinical trials and 0 publications supporting it, and the evidence pack’s own mechanistic review flags this specific pairing as the least biologically plausible of the ten candidates returned, most likely reflecting model noise rather than a genuine signal.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack
Predicted New Indication	Acromesomelic dysplasia, Hunter-Thompson type
TxGNN Prediction Score	99.99%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

A formal mechanism-of-action record is not available for tramadol in this evidence pack. However, the pack’s own rationale for a lower-ranked candidate (rank 7, juvenile idiopathic arthritis) does describe tramadol’s pharmacology: it is a μ-opioid receptor agonist combined with norepinephrine/serotonin reuptake inhibition, producing central analgesic effects.

Acromesomelic dysplasia, Hunter-Thompson type is a structural genetic disorder caused by GDF5 gene defects, affecting skeletal development. There is no pathophysiological pathway connecting a centrally-acting analgesic/monoaminergic mechanism to a congenital skeletal malformation — the two are mechanistically unrelated.

Notably, the evidence pack’s own analysis is explicit about this: it states that this top-ranked pairing is “the highest TxGNN score but the lowest biological plausibility,” and recommends treating it as a reference case for model-noise calibration rather than a genuine repurposing candidate. By comparison, several mid-ranked candidates in this batch — such as juvenile idiopathic arthritis (rank 7) — have a more coherent rationale (symptomatic pain control in an inflammatory joint condition), though even those are explicitly noted as non-disease-modifying, unsupported by any trial or literature evidence, and carry known pediatric opioid safety concerns (an FDA black-box warning for tramadol in children under 12 and post-tonsillectomy/adenoidectomy adolescents is referenced in that rationale). None of the ten candidates in this batch have any clinical trial or literature support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: This is an L5, model-prediction-only candidate with zero supporting clinical trials or literature, and the evidence pack’s own rationale identifies it as the least biologically plausible pairing in the batch (likely model noise). Separately, a Blocking data gap (missing SAHPRA/TFDA label warnings and contraindications) means the candidate cannot yet enter safety screening (S1) regardless of the indication question.

To proceed, the following is needed:

SAHPRA-approved Professional Information (warnings, contraindications) for tramadol — currently a Blocking data gap
Confirmed mechanism-of-action documentation from DrugBank or equivalent source
If a repurposing signal is still worth pursuing, re-examine mechanistically coherent candidates (e.g., symptomatic pain control in juvenile idiopathic arthritis) rather than the top TxGNN score, and actively search for trial/literature evidence on those
Clarification of regulatory pathway, since tramadol currently has zero SAHPRA registrations (Not Marketed)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.